FDA’s expanded allowance for non‑animal safety testing enables VivoSim’s human‑relevant models to cut drug‑development costs
Executive summary: On October 7, 2026 the FDA issued updated regulations permitting broader use of non‑animal testing methods for drug safety evaluation, and VivoSim Labs highlighted that its human‑relevant models are already reducing drug‑development costs. The change can lower reliance on animal studies, decrease testing expenses, and accelerate drug approval timelines, benefiting pharmaceutical companies and contract research organizations.
Who is involved: FDA (U.S. Food and Drug Administration), VivoSim Labs, and pharmaceutical developers adopting the new testing approaches.
Likely next (inference): Stakeholders will monitor adoption rates of the new methods and any further FDA guidance on non‑animal testing standards.
On October 7, 2026 the FDA released updated regulations that broaden the permissible use of non‑animal testing methods for drug safety evaluation. VivoSim Labs said its human‑relevant models are already helping to lower drug‑development costs. The move signals a shift toward alternative testing approaches that could reduce expenses and animal use in pharmaceutical R&D.
Timeline
- — VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods (GlobeNewswire)
Analysis — what this means
Sectors affected
- Pharmaceutical drug development
- Contract research organizations
Regulatory implications
- FDA’s updated guidance expands permissible use of in‑vitro human‑relevant models for safety testing, reducing dependence on animal studies.
Key entities
Sources
- VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods — GlobeNewswire
Related cases
- Sonorous Neurovascular secures FDA IDE approval to launch first U.S. pivotal trial of a venous sinus stent for pulsatile tinnitus
- CraniUS Therapeutics secures rapid FDA 510(k) clearance and a U.S. patent for its NeuroPASS cranial drug‑delivery system
- Dr. Oregonin secures FDA registration for OLTIS DENTAL‑X, launching a botanical oral‑care product grounded in a 1974 OSU discovery and two decades of South Korean research
- Roche’s BTK inhibitor fenebrutinib gains FDA filing acceptance for both relapsing and primary progressive MS, marking a potential first-in-class oral therapy
- Food safety attorney pushes FDA for mandatory warning labels on raw sprouts following multi-state outbreak
- XtalPi files first IND for AI-discovered gut-restricted pan-TRK inhibitor, marking clinical-stage transition